Replies to post #357572 on Innovation Pharmaceuticals Inc (IPIX)

[Jhawker]

Thanks for keeping it real here! Awesome post!

[Lemoncat]

Good thoughts. That's the bottom line. COVID is endemic and we have yet to find a decent therapeutic (though Gilead/Remdesivir is getting paid like one).

[steelyeye]

Excellent Post Farrell! All the drugs ending in "vir" and "mab" have done very little against this ever mutating Covid virus.

Brilacidin is the only virucidal antiviral now being tested as far as we know.

Brilacidin has significant immunomodulatory as well.

Go Phase 2 Brilacidin!

Go IPIX!

[BrilBlvR]

Excellent response and post Farrell. I know us longs appreciate you for all your insight. There are many of us that do not post much if at all here, but we do read. To those wishing IPIX to fail and driving the stock lower, thank you too for the cheap shares...

[biodoc]

Outstanding post, farrell90. Your post should be a sticky. It hits major points regarding limitations of current antivirals, how Brilacidin is different as a virucidal, and how Brilacidin has other properties that set it apart from other therapeutic candidates.

Dexamethasone has demonstrated a small benefit in reducing mortality and in decreasing time to discharge but it's pretty weak and the benefit is only for those with moderate/severe disease who require supplemental oxygen.
https://www.nejm.org/doi/full/10.1056/NEJMoa2021436

Remdesivir doesn't seem to do anything in late Covid but improves time to discharge in less severe cases.

Brilacidin really checks the boxes for what we're looking for in a therapeutic and it's a well designed trial with an appropriate Primary Outcome Measure. I hope the trial is well executed and proves sufficiently powered.

Primary Outcome Measures :
Time to sustained recovery through Day 29 [ Time Frame: Day 1 through Day 29 ]
Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale with response sustained through Day 29:

Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than for per protocol dosing or assessments, as appropriate);
Not hospitalized, limitation on activities and/or requiring home oxygen;
Not hospitalized, no limitations on activities.

[Basil22]

Great post. Thank you Farrell.

[DaubersUP]

Great post. Thank you. This thought and belief to why we are invested here is exactly why people should be excited. We are months away from finding out

[MackG]

farrell90, thanks for the sober and unemotional view of what's happening in the real world with the sundry treatments and vaccines available to combat covid-19 and it's variants. The world is in desperate need of Brilacidin. Your message will certainly help many here to grasp the full import of the multi-faceted superiority of Brilacidin as a highly effective therapeutic. The world may not yet know its name, but soon it will, as Brilacidin helps millions of people survive this deadly scourge. I await with tremendous confidence the results of Brilacidin's current clinical trial. Thank you so much for sharing your in-depth knowledge and insights on this important subject.

[To infinity and beyond!]

I hope that that people can carefully think through these arguments. The hallowed 3 in 1 of B v C? All Infectious disease docs advise against antibiotics in COVID unless there is a proven need. So much for that benefit- nota bene- it may cause MORE harm than benefit. Can you grasp that?

The antiinflamm effect- what's the correct dose for the correct response in a COVID patient? No one has even a clue about this, no lab data even about this with COVID let alone patient data.

The antiviral effect? Those who are hospitalized have very widespread viral illness already. Much damage has already been done and what is left is part inflammatory damage. And we just said how certain we are about B v C inflammatory benefit- we haven't even a CLUE.

Please think critically as you contemplate 3 in 1 exuberance